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Sstudy may be the major reason for smaller infarction size, which might translate to
a better long-term prognosis. Expansion of sample size may help to get more
persuasive conclusion.
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Background: To date, endovascular reperfusion is the essential method for the
treatment of AMI, however it has some negative aspects, such as reperfusion injury of
the myocardium, distal embolism, etc. Intracoronary administration of drugs provides
their fast transport to the target organ and can play a decisive role in the improvement
of the results of treatment of AMI.
Methods: The study comprised 253 patients (average age - 567 years) with acute
occlusion of the proximal or middle segment of the LAD and absent antegrade blood
ﬂow (TIMI 0), who underwent successful recanalization of IRA within the ﬁrst 6
hours after the onset of AMI. Prior to angiography, all patients were randomized into 2
groups. Patients from Group I (n¼126) received intracoronary Mexicor (0,2 g).
Patients from Group II (control, n¼127) did not receive. Intracoronary administration
was performed through a special microcatheter during 10 min. Blood samples for
markers of cardiomyocytes injury (Troponin I, myoglobin) were taken during
recanalization of IRA, in 12 and 24 hours after the procedure.
Results: In-hospital course of the disease was rather uneventful, 1 patient (0,8%) died
in Gr. I and 3 (2,3%) – in Gr. II. Average values of Troponin I at 12 hours after the
procedure in Grs. I and II were 31147 and 63239 ng/ml, respectively (p<0,05). In
the long-term after the procedure, in average – in 6,80,7 months, the survival in Gr. I
was 96,8%, in Gr. II - 87,6% (p>0,05). Baseline clinical indices in both groups were
not signiﬁcantly different. The increase of LV EF in Grs. I and II was 9,25,1% and
4,18,2%, respectively (p<0,05). We also noted a signiﬁcantly better dynamics of
contractility on infarct-related segments of the LV in Gr.I in comparison with Gr. II
(p<0,05) (table 1).
Conclusions: Our study suggests that intracoronary administration of metabolic
cytoprotector Mexicor Upoin accordance with a special technique limits reperfusion
injury of the myocardium and contributes to the preservation of structural and func-
tional integrity of cardiomyocytes after antegrade blood ﬂow restoration in IRA within
the ﬁrst hours after the onset of AMI.
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Background: Rapid time to reperfusion in STEMI is required to maximize
myocardial salvage. Conversely, reperfusion success is diminished in patients pre-
senting late. In the randomized MASTER trial, the MGuard Embolic Protection Stent
was shown to improve TIMI-3 ﬂow and ST-segment resolution (STR) compared to
control DES or BMS. We thus sought to evaluate the impact of symptom onset to
balloon time on the efﬁcacy of this novel device.
Methods: The MGuard is a novel thin-strut metallic embolic protection stent with
a PET micronet covering designed to trap and exclude thrombus and friable athero-
matous debris and prevent distal embolization. A total of 433 patients with STEMI
<12 hours in duration undergoing PCI were randomized to either the MGuard stent
vs. a control (BMS or DES) stent.
Results: Symptom onset to balloon time was <180 minutes in 157 pts, and 180
minutes in 253 pts. Pts reperfused early vs. late were more likely to achieve complete
STR (58.6% versus 47.0%, P¼0.02), and had more rapid cTFC (15.0 vs. 18.0 frames,
p¼0.005). In the entire patient cohort, complete STR and TIMI-3 ﬂow were signiﬁ-
cantly improved with the MGuard stent compared to control stents (57.8% vs. 44.7%,
P¼0.008; and 91.7% vs. 82.9%, p¼0.006, respectively). The results of
stent randomization according to symptom onset to balloon time (SBT) appear in the
table.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Compared to standard stents, the MGuard Embolic Protection Stent
improves reperfusion success in both patients with rapid and delayed time to reper-
fusion, although the absolute magnitude of beneﬁt may be greater in patients with
delays from symptom onset to reperfusion.
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Background: Longer delay from symptom onset to reperfusion has been linked to
increased mortality and worse clinical outcome. The mechanism underpinning this
association is not entirely clear. Thus, we evaluated the impact of the delay from
symptom onset to reperfusion(<3 vs. 3 h) on infarct size and clinical outcomes at 30
days and 1 year in patients with STEMI) treated with primary PCI.
Methods: The INFUSE-AMI trial randomized patients with anterior STEMI under-
going primary PCI with bivalirudin anticoagulation to intralesion (IL) bolus abcix-
imab vs. no abciximab, and to thrombus aspiration vs. no aspiration. The primary
endpoint was cMRI infarct size (IS, % of left ventricular mass) at 30 days. Time to
reperfusion was classiﬁed as <3 vs. 3 h.
Results: There were 280 (62%) patients with <3h delay and 170 (38%) with 3h
delay. Patients with longer delay were signiﬁcantly older, more often women and
diabetics. IS was marginally smaller in patients with shorter delay to reperfusion
(16.4% [6.5, 22.9] vs. 18.1% [10.5, 24.8], respectively, P¼0.07). However, shorter
delay to reperfusion was not associated with higher rates of ﬁnal TIMI 3 ﬂow or
myocardial blush grade 2/3. There was signiﬁcantly lower mortality and morbidity at
30 days and at 1 y in patients with shorter delay (Figure). Delay 3h was an inde-
pendent predictor of 1-year MACCE, but not of death or MACE.
Conclusions: Even with contemporary primary PCI, longer delay to reperfusion
negatively impacts clinical outcome. This effect appears not to be mediated by less
successful reperfusion or by a markedly larger infarct size.TCT-231
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Background: Patients with a history of CABG have traditionally been excluded from
randomized studies comparing PCI and CABG. The optimal revascularization strategy
in these patients is not well deﬁned. We therefore sought to evaluate the relationship
between revascularization strategy and outcomes in patients with prior CABGacts/POSTER/STEMI/NSTEMI/ACS B75
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scale ACUITY trial.
Methods: ACUITY was as an international randomized trial of different antith-
rombotic and antiplatelet regimens in 13,819 patients with moderate and high-risk
NSTEACS. Revascularization strategy was per discretion of the local clinical team.
We compared patients with a history of prior CABG by revascularization strategy
(CABG vs. PCI).
Results: A total of 1,433 NSTEACS patients with previous CABG underwent
revascularization in the ACUITY trial. Of them, 1,360 (94.9%) underwent PCI and 73
(5.1%) underwent redo CABG. Redo CABG was associated with greater rates of post-
procedural acute kidney injury (AKI) (30.0% vs. 10.8%, p<0.0001) and 30-day major
bleeding (63.1% vs. 6.6%, p<0.0001) compared with PCI. CABG (vs. PCI) was an
independent predictor of AKI and major bleeding. At 1-year, redo CABG rather than
PCI was associated with higher rates of MI (21.2%% vs. 13.5%, p¼0.04), mortality
(13.8% vs. 5.4%, p¼0.0007), and MACE (39.2% vs. 27.8%, p ¼0.007), whereas
ischemia-driven target vessel revascularization was more common in the PCI group
(12.4% vs. 1.7%, p¼0.02). By multivariable analysis, redo CABG was independently
associated with 1-year mortality and MACE (Table).
Conclusions: Patients with prior CABG presenting with NSTEACS who were
managed with redo CABG rather than PCI had higher rates of short- and long-term
adverse events. While not a randomized trial, these data suggest that PCI should be the
favored procedure in the NSTEACS patient with prior CABG in whom revasculari-
zation is required.Table. Independent Predictors of Events
Independent predictors of 1-year mortality
Male sex 3.38 [1.47, 7.76] 0.004
Acute kidney injury 2.96 [1.67, 5.26] 0.0002
CABG vs. PCI revascularization 2.94 [1.37, 6.25] 0.006
Diabetes 2.22 [1.30, 3.82] 0.004
Biomarker elevation 2.11 [1.21, 3.68] 0.009
Age (10-year increments) 1.79 [1.31, 2.45] 0.0002
Baseline hemoglobin 0.83 [0.71, 0.97] 0.02
Independent predictors of 1-year MACE
CABG vs. PCI revascularization 1.59 [1.03, 2.50] 0.04
Acute kidney injury 1.57 [1.15, 2.14] 0.004
Previous PCI 1.43 [1.13, 1.82] 0.003
Biomarker elevation 1.26 [1.00, 1.58] 0.046
AKI ¼ acute kidney injury; CABG ¼ coronary artery bypass graft; MACE ¼ major adverse
cardiovascular event; PCI ¼ percutaneous coronary intervention.TCT-232
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Background: Acute hyperglycemia on admission increases risk of cardiac events after
ST-elevated myocardial infarction(STEMI) patients. However, it still remains unclear
whether acute glycemic variability has the important prognostic signiﬁcance. There-
fore, this study aimed to evaluate the relationship between cardiac events and the
variability of glucose levels by a continuous glucose monitoring system (CGMS).
Methods: This prospective study enrolled 40 patients (age 7014 years, 78 % male)
with STEMI. All patients were inserted CGMS on admission and were measured at
least 48-hours. CGMS provide with glycemic excursion displayed at 5-minutes
intervals, 576 points during 48 hours. Primary end points were the incidence of major
adverse cardiac events (MACE) at 1 year, including cardiac death, myocardial
infarction, and heart failure.
Results: We found 3 patterns as the change of glucose wave (ﬁgure). The three
patterns were deﬁned persistent hyperglycemic pattern (PHP), intermittent hypergly-
cemic pattern (IHP), normal glycemic pattern (NGP). Signiﬁcant differences were
observed regarding the mean amplitude of glycemic excursions among 3 patterns
(12061mg/dl, 9341mg/dl, and 4516mg/dl in PHP, IHP, and NGP, respectively
p¼0.0004). The MACE incidence rates were 75%, 31%, and 5% in PHP, IHP, and
NGP, respectively, (p¼0.17).B76 JACC Vol 62/18/Suppl B j October 2Conclusions: A signiﬁcant relationship was observed between cardiac events and the
variability of hyperglycemic levels during 48 hours after coronary interventions.
Patients with PHP, even IHP, were associated with an increased risk of cardiac events.TCT-233
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Background: The purpose of this study was to evaluate the effects of statin treatment
in patients with ST-segment elevation myocardial infarction (STEMI) according to
completeness of revascularization.
Methods: From a total of 6657 STEMI patients who were registered in Korean Acute
Myocardial Infarction Registry from November 2005 to December 2007, 766 patients
were selected by subsequent propensity score matching (Age-, Sex-, LDL-cholesterol
level-, LVEF-) for 4 groups; complete revascularization with (CR+Statin, n¼199) or
without statin treatment (CR-Statin, n¼193) and incomplete revascularization with
(ICR+Statin, n¼178) or without statin treatment (ICR-Statin, n¼196). Major adverse
cardiac events (MACE) such as all-cause death, myocardial infarction (MI), target
vessel revascularization (TVR) were evaluated for 12 months.
Results: The rate of in-hospital mortality was not different among groups (3.0% in
CR+Statin vs. 5.7% in CR-Statin vs. 3.4% in ICR+Statin, 3.6% in ICR-Statin,
p¼0.520). During 12 months follow-up, MACE was developed in 15.5% of total
patients (10.1% of CR+Statin, 13.5% of CR-Statin, 15.2% of ICR+Statin and 23.5%
of ICR-Statin, p¼0.002). TVR (4.0% of CR+Statin vs. 5.2% of CR-Statin vs. 6.2% of
ICR+Statin, 16.3% of ICR-Statin, p<0.001) were signiﬁcantly different among groups
during 12 months follow-up. In subgroup analysis of patients with complete revas-
cularization, statin+ group has decreasing trend of MACE than statin- group, but not
signiﬁcantly (10.1% vs. 13.5%, p¼0.293). In case of patients with incomplete
revascularization, statin+ group has signiﬁcantly lower MACE than statin- group
(15.2% vs. 23.5%, p¼0.043).
Conclusions: The treatment of statin in patients with STEMI patients was considered
to improve clinical outcomes. Moreover, patients with incomplete revascularization of
STEMI performing primary PCI had more beneﬁcial effects of statin therapy than with
complete revascularization.7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
